Fusion Antibodies Income Statement

Financials in millions GBP. Fiscal year is April - March.

Millions GBP. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	2.11	1.97	1.14	2.9	4.8
Revenue Growth	7.38%	72.97%	-60.84%	-39.55%	15.22%
Cost of Revenue	0.88	1.54	1.18	2.33	2.33
Gross Profit	1.23	0.43	-0.05	0.57	2.47
Selling, General & Admin	3.09	2.05	2	3.13	3.03
Other Operating Expenses	-0.87	-0.15	-0.01	-0.01	-0.03
Operating Expenses	2.34	2.01	2.23	3.47	3.79
Operating Income	-1.11	-1.58	-2.27	-2.89	-1.33
Interest Expense	-0.02	-0	-0.01	-0	-0.01
Interest & Investment Income	0	0.01	0	0	0
Currency Exchange Gain (Loss)	-0.02	-0.05	-0.02	0.04	-
EBT Excluding Unusual Items	-1.15	-1.63	-2.29	-2.86	-1.33
Pretax Income	-1.15	-1.63	-2.29	-2.86	-1.33
Income Tax Expense	-	-	-0.06	-0.26	-0.13
Net Income	-1.15	-1.63	-2.23	-2.6	-1.2
Net Income to Common	-1.15	-1.63	-2.23	-2.6	-1.2
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	115	96	56	26	26
Shares Outstanding (Diluted)	115	96	56	26	26
Shares Change	20.26%	72.58%	113.55%	0.27%	1.91%
EPS (Basic)	-0.01	-0.02	-0.04	-0.10	-0.05
EPS (Diluted)	-0.01	-0.02	-0.04	-0.10	-0.05
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Free Cash Flow	-1.17	-1.37	-1.77	-1.87	-0.59
Free Cash Flow Per Share	-0.01	-0.01	-0.03	-0.07	-0.02
Gross Margin	58.34%	21.88%	-3.96%	19.79%	51.39%
Operating Margin	-52.56%	-80.15%	-200.00%	-99.76%	-27.61%
Profit Margin	-54.45%	-82.75%	-195.95%	-89.49%	-25.00%
Free Cash Flow Margin	-55.59%	-69.92%	-155.90%	-64.39%	-12.25%
EBITDA	-1.06	-1.47	-2.05	-2.55	-0.65
EBITDA Margin	-50.09%	-74.96%	-180.81%	-87.80%	-13.48%
D&A For EBITDA	0.05	0.1	0.22	0.35	0.68
EBIT	-1.11	-1.58	-2.27	-2.89	-1.33
EBIT Margin	-52.56%	-80.15%	-200.00%	-99.76%	-27.61%